Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

When Baso Fibonacci visited Barcelona more than 20 years ago, he marveled at how artists there didn’t sneak around when creating street art: “It opened my eyes to what could be done in the renegade ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Abstract: Heterogeneous device-edge-cloud computing infrastructures have become the backbone of modern telecommunication operators and Wide Area Networks (WANs), providing multi-tier computational ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Amidst the AI boom transforming various sectors, Recursion Pharmaceuticals (NASDAQ: RXRX), a previously beaten-down AI-biotech, is showing signs of a rebound. Its stock has skyrocketed 25% in the past ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Recursion Pharmaceuticals' stock has been volatile, and is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. The company's Q4 FY24 earnings showed ...

The Project Fibonacci Foundation is a dynamic organization dedicated to transforming education and opening doors to innovative opportunities for young minds. With a mission centered on empowering ...

Abstract: Current synthetic aperture radar (SAR) missions with short repeat times bring the opportunity to get large-scale deformations in near real-time. Since nonstationary deformation is more ...